PYXSPyxis Oncology Inc. Common Stock
3.080USD-8.61%Mkt Cap: 256.90M $P/E: —3d ago
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consist…